Trial Profile
A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Padeliporfin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Steba Laboratories
- 09 Jun 2016 Results published in the Journal of Urology
- 14 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2012 Planned end date changed from 1 Apr 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.